Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products ...

Avalere Health, a 2025 MM+M Agency 100 honoree, named Rhiannon Meaden, PhD, as head of medical strategy and transformation.

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis, Pidilite, Aditya Birla Sun Life AMC, Heritage Foods , and D. B. Corp are the 5 key companies to trade ex-dividend ...

The pharmaceutical company posted higher earnings and sales for the second quarter, and said longtime financial chief Harry ...

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...